Top San Francisco Bay Area, CA Pharmaceutical Companies (66)

GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...

Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it. Our Founders and members of the Board are a group of esteemed, world-class scientists from the University of California,...

Helping the brain work better with focused ultrasound. Treating neurological disorders today and enhancing human experience tomorrow.

SmithRx is committed to providing a straightforward approach to reducing drug costs and improving health outcomes. We understand that reducing pharmacy costs is top of mind for us all. We utilize cloud technologies to deliver the most streamlined and cost-effective PBM solution: one that is modularized and can be tailored to meet individual needs. Our compelling value proposition can be summarized...

Multiply Labs develops advanced robotic systems that manufacture individualized drugs at scale. Our products are enabled by the combination of pharmaceutical science with robotics technology. Multiply Labs has built and operates a unique robotic pharmaceutical manufacturing facility in San Francisco.

At Enable Medicine, we index biological data into highly detailed maps of human disease. This atlas is utilized to guide novel drug target discovery, identify biomarkers of therapeutic response, and develop optimal treatment strategies. Our lab in Menlo Park, California, generates high-parameter biological datasets, and our cloud-based operating system allows researchers to organize, process, query, and analyze this data at...

Triton Medical Robotics is on a mission to transform clinical practice and improve the lives of patients, caregivers, and society as a whole by creating highly innovative, category-defining robotics that give doctors incredible new capabilities to provide significantly better care. Triton, a division of Neptune Medical, is an innovative, venture capital funded medical device startup headquartered in Silicon Valley in Burlingame,...

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and...

Endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely...

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of...

At BioNex Solutions, we develop instrumentation and integrated systems that solve the most demanding applications in biopharmaceutical, biotech, and academic research. Our hardware and software philosophy is to design single-purpose, high performance modules, and integrate them to produce the desired functionality. Rather than push a single, generalized product that tries to meet the needs of every customer, we prefer to...

Drug Hunter™ is an essential subscription service for R&D-focused organizations turning molecules into medicines. Every day, drug discovery strategies, tactics, challenges and solutions are disclosed, but the knowledge is fragmented across journals, conferences, patents, databases, news, company reports, filings and endless other sources, making it challenging to find and apply. Drug Hunter’s experts keep you current by connecting the dots, distilling industry...

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as NASH, obesity and cancer. Terns’ pipeline includes four clinical stage development programs including a THR-β agonist, an allosteric BCR-ABL inhibitor, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more...

Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Berkeley, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more about our mission to decode the language of life...

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with...

We are a biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug...

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than...

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for...

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). Our pipeline also includes additional investigational products and lead...

Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. Our pipeline includes two investigational oral SYK inhibitors, entospletinib and lanraplenib, which are being developed to treat acute myeloid leukemia (AML). Together the compounds have the potential to target mutations present in more than two-thirds of patients with AML....